3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
4
Neoplasms
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Sepsis
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Malignant mesenchymal tumor
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hematologic Diseases
1
Graft vs Host Disease
1
Gliosarcoma
1
Glioblastoma
1
Fever
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Radiosurgery
23
Radiotherapy
20
Temozolomide
17
Lomustine
9
Bevacizumab
8
Surgical Procedures, Operative
7
Procarbazine
6
Vincristine
5
Nivolumab
5
Memantine
5
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Etoposide
4
Cisplatin
4
Carboplatin
4
Specimen Handling
3
Sodium Chloride
3
Radiation
3
Methylphenidate
3
Mental Status and Dementia Tests
3
Granulocyte Colony-Stimulating Factor
3
Gefitinib
3
Cyclophosphamide
3
Corticotropin-Releasing Hormone
3
Carmustine
3
icotinib
2
etoposide phosphate
2
efaproxiral
2
X-Rays
2
Tranexamic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Brain Neoplasms
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled